Drug Profile
Research programme: PP2A/SET modulators - SupremeCure Pharma
Alternative Names: EMQA; TD 19; TD XLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator SupremeCure Pharma
- Class Alkynes; Antineoplastics; Diamines; Quinazolines; Small molecules
- Mechanism of Action Protein phosphatase 2A stimulants; Protein-protein interaction modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver cancer; Non-small cell lung cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Liver-cancer in Taiwan
- 28 May 2022 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in Taiwan
- 10 Apr 2018 Preclinical trials in liver cancer in Taiwan (unspecified route) prior to April 2018